Download Files:
TCV-309 (chloride)
$280 – $2,100
Products Details
Product Description
– TCV-309 chloride is a potent and specific platelet activating factor (PAF) antagonist. TCV-309 chloride specifically inhibits PAF-induced aggregation of rabbit and human platelets, and [3H]PAF binding to rabbit platelet microsomes with IC50 values of 33 nM, 58 nM and 27 nM, respectively. TCV-309 chloride has beneficial effects in anaphylactic shock[1][2].
Web ID
– HY-19121A
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C30H34BrClN4O4
References
– [1]M Poeze, et al. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group. Shock. 2000 Oct;14(4):421-8.|[2]Terashita Z et al. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. J Pharmacol Exp Ther. 1992 Feb;260(2):748-55.
CAS Number
– 121494-09-5
Molecular Weight
– 629.97
Compound Purity
– 95.0
SMILES
– CCC[N+]1=CC(C(N(CCC(NCCOC(N2CC3=C(C=CC=C3)CC2)=O)=O)C4=CC=CC=C4)=O)=CC(Br)=C1.[Cl-]
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 6.3 mg/mL (ultrasonic)
Target
– Platelet-activating Factor Receptor (PAFR)
Pathway
– GPCR/G Protein
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
